Okay, I think we're ready to go. Hi, everyone. Thank you for joining the EBR Q3 2026 Results. As you all know or probably know, we did pre-release our caseload and an estimate of the revenue, so this will largely reflect that. Then we'll go into a little more detail than we had in the last presentation with the early results. Let me just quickly go through our investment and clinical thesis. Of course, we've got regulatory approval in the U.S. I think one of the great stories about the EBR launch is the premium reimbursement that we have. We have more good news on that. We continue to get incremental reimbursement, and it's looking more and more favorable all the time. It started out in a very good position, and we'll talk more about that in this presentation. We do have early momentum.
We did have a stumble in the last quarter that we'll address, but overall, we're really pleased with the direction we're going. We're going to focus more and more on account depth, and that's a big part of the pre-release that we discussed, the changes that we made to commercial leadership, and the refocus of our U.S. commercial team, and we'll talk more about that in detail. We're now in our new facility. It's not yet certified by FDA, but that's imminent, and I'll talk about that as well. This facility gives us great scalability and future growth. It also gives us an opportunity to drive down cost of goods and improve margins, and we'll address that as well. With that, I'll go into some of the key milestones and walk through some of the highlights of the announcement.
We did complete 40 cases in the third quarter. That brings us to the total commercial cases at 157 through the third quarter. The implant volumes, as we said, were below our company's or internal forecast and below the analyst expectations in the quarter, and that was especially driven by September. We were doing probably what we expected in the months before that. Then we made some changes in September that really temporarily slowed down our growth and our caseload. We made some leadership changes, and concurrent with that, we also changed the commercial execution strategy and had our team focus more on driving cases in accounts that we've already started. We haven't frozen new sites or new cases or new physicians.
We just de-emphasized and made it more focused, give the reps more focus on staying in their territories and only starting sites where we have territories that could then support them. The way our sales process works is we don't just sell and start a site and then wait for the orders. We start a site, train the physician, and then the sales team has to spend time in that account to help drive internal referrals to the physicians. For example, many of our physicians, they're global thought leaders, KOLs, and they travel and go to many meetings, and when they're not there, we need to be actively engaged with the sites so that the support staff is looking for appropriate patients. The physicians aren't seeing every patient that comes through their clinic. They only see them occasionally or when there's a high need.
When we have salespeople working within an account, they can work with the There's called a pacing clinic. This is where the patients routinely go in for checkups on their implants, on their pacemakers. That's a great place for us to have interaction with the staff there to make sure that they're top of mind, that WiSE is top of mind. When they see a patient that in the past they didn't have a solution for, they think of WiSE, so they're really looking out for these sorts of patients. That happens by having constant touch points with our sales team. So we really are focusing them, encouraging them, and not just encouraging, but demanding and incenting them to spend time in accounts that they've already started.
Again, it doesn't mean we won't start any new accounts, but we're going to de-emphasize that and lean in the sites that we started. The other change we made is when we made the leadership change, I stepped into that role. I'm now managing directly the commercial team. We do have an active search for a new Chief Commercial Officer, but in the interim, that's my job. I've been traveling in the field now, and before that, I had a lot more focus on investor side of the job function, and I would be traveling to Australia probably 5x or 6x a year to go to investor conferences and meet with some of you. Since this transition, I have not been to Australia.
I've been focused on U.S. travel, both meeting with clinicians, with hospital administrators, and with our sales team, and trying to see firsthand how things are going, seeing if I learn anything new from that interaction. It's been a really great thing to do. Have had some really good interaction with, again, clinicians are very supportive, are looking for patients, are really excited to continue their adopting WiSE in their practice. I've had some really great conversations with administrators and what the economics are for their site and how it's a benefit to them to adopt the WiSE technology. Then also just reinforcing with the sales team, the messaging, the focus, and making sure that through repetition and one-on-one interaction, that everybody in the field is getting the same direction, the same uniform messaging on the strategy to execute going forward.
Beyond the commercial side of things, we made progress on our manufacturing facility. We completed our FDA inspection. It's got a lot of capacity for as long as we can see. It's not just capacity for scalability, but also for cost of goods and margin improvement. So this facility and the capital investments that we made in the last year will really help drive down our cost of goods. It doesn't happen overnight. It's a gradual process, but we will make some significant improvements as we move forward now that we can start building in the new facility. We did complete the capital raise, and I know it's top of everybody's mind, how are we managing that cash? We hear all the questions and the concerns about our burn. We do have a focus on being fiscally responsible and targeting our investments.
We're looking at every spending account that we have and making sure that we're focusing on where the ROI is. Really, it's sales, for sure, commercial. We've got compliance issues and studies that we have to fund. For example, it's a regulatory commitment requirement that we run the post-approval study. We definitely want to run the WiSE-CHOICE study, which is the National Coverage Determination study. We need to maintain our compliance, and we want to keep investing in cost of goods. Those are the things that we're going to really protect. Then we're going to look at other places where we could lower our investment and be more prudent with the cash that you've entrusted us with. Now I'm going to ask Andrew to talk through the commercial progress to date.
Thanks, John. We shared these KPIs during our preliminary results webinar, but to recap, the importance of these four KPIs as they are what we believe the important indicators to predict our future commercial success. Physicians trained, there were an additional 10 physicians trained during Q3, now bringing the total to an even 100. An additional five purchasing contracts were signed during the quarter, bringing us total to 57 signed contracts. We now have activated or implanted in 40 hospitals across the U.S., and 20 more of these, well, basically half of these hospitals have now implanted three or more WiSE systems. With our commercial cases completed, the headline result was 40 implants in the quarter, bringing the total to 157 since the beginning of Limited Market Release.
As we shared previously, that drop-off was in September, which was half the average of July and August implant numbers. As John already highlighted, that drop-off was a result in the necessary organizational changes we made and refocusing on that strategy of going deep, not broad, really to focus on generating higher and sustainable utilization rates. Looking ahead, we can expect to see a drop-off in the number of new sites contracted and physicians trained. Really, by having too many sites to adequately service properly, our reps in the field were really starting to spread thin and not able to focus on deep penetration. That really comes from an ongoing presence in the accounts. Going deep means spending time in the cath lab.
The hospitals we work in will have between 10 and 20 electrophysiologists. The majority of the sites in that first year, we're just working with one EP. There's nine to 19 other EPs that are also implanting lead-based CRT. Spending that time in the cath lab to identify those other patients that had a failed implant. It's spending time in the pacing clinic, working with the physiologists and nurses there to identify those patients who've had a chronic lead failure, those patients that they're programming those leads off. It takes time to build those referral pathways. It takes time that we're at the forefront of their mind so they can be referring these patients onto our implanters.
Importantly, even if we didn't open another new account, with 40 active accounts, if we're spending time going deep, building those internal referral pathways, and if we can get our utilization rate up to one implant per month, that equates to an annual run rate of just under $30 million.
Thanks, Andrew. I'll ask Gary to go through the financial results that we presented today.
Sure. Thank you. Here, just in summary, this encapsulates our results for the quarter. We can see the commercial implant figure that we've already discussed and its attendant revenue. That came in around $2.5 million U.S. Our gross profit is displayed here as our OPEX, and we travel down through our net loss. I want to call your attention to two things. One, from a gross profit percentage perspective, we've discussed really over the last year plus our use of previously fully expensed inventory and how that was helping us from a margin perspective. That pile has been consumed as of the end of the quarter, and so we won't be enjoying any further benefit in that regard.
However, if you look at the actual gross profit performance, if you strip out the consideration for that zero-cost inventory, you'll see that over the last several quarters, we've gone from, say in the first quarter, our natural gross margin, if you will, was negative 23, 25 points, and now it's -9 . So, we're definitely heading in the right direction. That improvement is really kind of a product of greater volume. The operators that are making our products have more experience. We've improved some fixturing and things of that nature, and so we're starting to see the benefit of that. A lot of the spend that we've been undertaking and will undertake in the future is in R&D and pertains to various and sundry products and process improvements that will improve our margins over time.
As far as OPEX goes, what we'll see, you see a slight drop from third quarter, sorry, from second quarter to third quarter, and we're knee-deep, if you will, in reviewing all of our spending. We're looking for anything that could be considered discretionary or we can push off or delete, and making every effort to make sure that our spend is highly focused on the areas that John had outlined from a compliance perspective, margin improvement expenditures, and commercial expansion. All of those things combined are really sort of focusing us on trying to keep the leanest possible spend that we can put forward.
Thanks, Gary. I'm just going to go over some near-term milestones. This was released, but you all probably saw this. We had CMS granted us higher reimbursement rate for the inpatient procedures under the NTAP, and so this was effective October 1. Now, just to put this in context, most of our patients are outpatient, so this is great news, but it's not a step function sort of a benefit. What it does is it takes away some of the potential headwinds for physicians that need to treat patients on an inpatient basis. Just to clarify, in the U.S., an inpatient means if a patient spends two midnights in a hospital, it's inpatient. If they spend one night, it's considered outpatient, and that's what triggers one payment structure versus the other. Most of our patients are outpatient, but we also have good news there.
They had CMS, they always do a proposed rule early, they wait for comments, and then they issue a final ruling, and the final ruling was actually higher than they had proposed initially. There was some lobbying efforts there to make sure that that remained very healthy and generous for our procedure, and that's probably the more important of the two, although we'll take all the good news on reimbursement we can get. We're really pleased with both. The National Coverage Determination, and this gets confusing because the first one where we're talking about the reimbursement rates, that's the amount of money that they pay for the procedure. Coverage is whether they pay for it at all, whether it's a yes, no, are they going to cover that procedure. The way that CMS is structured, or Medicare in the U.S., there's two different schemes.
One is kind of the conventional Medicare, which is managed by the government, and that's always been covered. It's called implicitly covered. So, there's not a National Coverage Determination which declares it affirmatively, but it's a given. But that's about half of all patients in Medicare. The other half are managed under what is called Medicare Advantage, and Medicare Advantage is contracted out to private insurers to manage, and they have discretion. They can deny coverage. Oftentimes, even if they deny it, they will cover it under appeal, but that adds a lot of friction. Sometimes if it's denied and it's appealed once and people don't pursue it, they just give up and move on. That is a significant headwind. The National Coverage Determination forces the Medicare Advantage carriers to cover all the procedures. Typically, that's probably a five-year process, and sometimes companies never get it, new technologies.
For new technology that is not already covered in a parallel product, it can be a really daunting long-term process. We are on the verge of getting this, by all accounts. They are supposed to issue a final decision early in December, and then assuming that is positive, which we have every reason to expect it will be, then it would be implemented late in the first quarter. Then after that, if there is a patient covered under Medicare Advantage, they would not be denied any coverage. We say that doubles the patient coverage or covered patient base because that is roughly half of the Medicare population, which is the vast majority of all the patients that would be treated with WiSE. All great news there. Then the final near-term milestone would be the certification, FDA certification of our new facility. We did have our inspection.
We announced this on ASX. We had two observations, which is really common on our inspection in the old facility before we had FDA approval, the final inspection before FDA approval. We had no observations, which is really remarkable. That was great news. We typically expect two to three, sometimes four. Getting two observations is not a surprise. They were paper exercises, so it is basically fixing something in our quality system. We have completely fixed one, we are about to complete the other, and then we still expect full certification by the end of the year. We are moved in and occupied and starting qualifying all the equipment, but we are not able to ship product from this facility until we get that final certification. Again, that seems to be imminent.
With that, I know there are a number of questions that came in early, and there may be some coming in late. We do have a hard stop on the half hour, so we will do our best to answer as many as we can. A lot of them are somewhat similar or redundant, so we will collapse them into fewer total questions. Andrew, if you could go down the list and
Yep. We do have a number of, actually, the majority of questions are actually forward-looking requests asking for updates on planned procedures for the quarter, projected cash burns. John, do you want to just comment on a high level on that?
Yeah, it's pretty much what we've said already. We're not going to give guidance, direct guidance, but we are looking at all of our spending accounts, and we're in our planning process right now. We're going to prioritize commercial, so we want to keep making sure that we're driving revenue and case coverage and so on. The sales line will keep investing there. There's certain compliance things that we have. We're going to do the post-approval study, or we've been doing that. We'll continue to enroll there, and there's an expense for that. We're going to fund the National Coverage Determination study. The first one, the formal one that I mentioned, the post-approval study is called WiSE-UP. The National Coverage Determination study or Coverage with Evidence Development study is called WiSE-CHOICE, and we'll be funding that next year.
We'll continue to invest in R&D, particularly where it drives down cost of goods, so design for manufacturing and bringing a lot more processes that are now at contract manufacturers, moving them to the new facility. That takes R&D resources, engineering resources to move those functions over and qualify them and do that in a compliant way. We'll continue to invest in that. We're going to look at everything and make sure that nothing is not on target and really what we think would be the best ROI and use of the cash that you've all gifted us with.
Thanks. The next question is, can you provide an update on how close you are to having AVEIR on label?
Oh, I can't give you an update on timing. That's something, oh, that's another priority. Thank you for asking that, though. That goes back to what are we investing in. That's not a huge investment, but it takes people and effort, and so we're continuing to qualify that. When we have something tangible that we can release, we would do that through an ASX announcement, but it is a priority for us.
Thanks. With the increased NTAP and inpatient reimbursement, would you expect to see a shift away from outpatient treatment towards inpatient treatment?
Yeah, I mentioned that on the prior slide. We do not expect to see a shift. I do not think it is going to drive behavior. Really, the patient has to be treated the most clinically efficacious way for them. So if a patient has numerous comorbidities or other illnesses and they really need to spend several nights in the hospital, then those patients would be treated as an inpatient regardless. If they are not in that condition and they can be treated with one overnight stay, they will be discharged. So it makes the whole package better, but it is not going to skew which way it goes. I expect the ratio, which is predominantly outpatient, to continue.
The next question is, have you submitted your response to the two observations from the facility inspection or received any feedback from the FDA on your response?
Yeah, one response is in and one is imminent, and we expect that to then go through smoothly. We do not have any response from FDA, but our job is to answer the observation, and we are confident that we are doing that for the observations.
Could you comment on the Bell Potter report, which significantly reduced share price and expected two further cash raises?
We don't give guidance, so the analysts independently make their determinations. There's three other analysts as well. We're still comfortable with the overall guidance, the consensus, and can't really comment on any one.
Is it time to move off the ASX and into Nasdaq, given that the ASX clearly doesn't value the company?
Well, I don't know that I'm going to I'm not sure how to answer that. We think the ASX has been a great vehicle for us, and I think what the ASX expects is continued growth and results. We didn't deliver that last quarter, and I think we will be showing better results going forward. That's a forward-looking statement, but not in a quantitative way. We're still optimistic about the future, and I think when we start showing results, the ASX will reward us.
Are you to provide an update on the IP issue? Is it a major problem?
I will not provide an update, but no, it's not a major problem, and that's something that I can't go into detail, but it's not an impediment to anything that we're doing.
An emailed in question, from your time in the field, are you identifying any barriers to adoption?
No. So, there's a book called "Crossing the Chasm," if anybody's interested, and it's sort of one of my mantras that I go by. When you're introducing a new technology, and that applies to the tech world, it goes across industries, but you find and look for the early adopters, and the early adopters are the clinicians that see the value in WiSE. We're not even selling them. They're already there. We kind of have to find each other, and then they're committed to it. They're in the right structure, the right organization. So, healthcare in America is very heterogeneous, and so it's not the same, even within a city, between centers, they have different philosophies, different cost structures, different patient flow. So, our job is to find and identify those early adopters where it works for them and where we are today is a good fit.
Over time, our cost of goods come down, we'll be more streamlined, it'll be more mainstream, and then it'll be available and work in more and more sites. What I saw was the sites, I've been meeting physicians that are really engaged, really excited to use it, and then also talking to administrators and seeing what works for them. For some administrators, it's about what's the gross, what do they net after expenses, and that's really important to them. But it varies around the country, so we have to find the ones where the economics work really favorably for them today. Others are more about throughput, or some want to be referral centers, and they want to be the first center in their region to offer a new technology, and not just offer it for one patient, but to adopt it.
I had a great conversation at one site that was kind of their currency. They said they're making money on the WiSE procedure, so the reimbursement is generous. But they said, but that's not even the main driver for them. It's a driver, but for them, it's also they want to be a referral center, and they want to offer everything that is important for their patients and to be, again, be a catchment or referral from other sites in the area. They said, "We have to be involved with WiSE because that's important. We want to be leading edge and be able to offer all new technologies." So early on, we're trying to pair up those physicians and sites that really value what we offer, and then if somebody's more on the fence, we come back later.
We don't need to get everybody now in order to be really, really successful, have a great business, high growth, high margin business, so it's being very focused in how we do that. The other thing that was interesting is, how much time I got? A minute and a half left. Going into some of the bigger sites and talking to different physicians, different electrophysiologists that could do our procedures, one of them's trained as an example and as an advocate. The other one's more skeptical, and that's okay.
They go, "Well, I want to wait and see what my partner does and see how it goes, and we'll get that physician in a couple months or next year." It's fine because we've got the one clinician that's dedicated, and also if the untrained physician comes across a patient, they go, "Oh, now that I had that conversation, it reminds me there is something for this patient." They can refer them to the doctor that's trained. That's part of the focus strategy, is having our salespeople in the accounts, even when there's not a case to be done, they're in there having these discussions, making sure that our technology is top of mind, because these are really busy physicians. They've got a lot on their mind.
It's not always like they're not thinking about something novel like WiSE, and it's our job to be in there making sure that it's front and center all the time.
Just to build on that, it'll answer the next question, which was, in the medium- and long-t erm, what would you expect the average number of WiSE implants per month to be done by a trained cardiologist? Dr. Bob Canby recently joined us as our Chief Medical Officer. He actually had implanted the first commercial implants in the U.S., and has been actively involved in our training program. During our road show, two weeks ago now, he was saying that he felt he would be comfortable doing three implants per month, and that's fitting in amongst the other procedures they're doing, AF ablation, VT ablation, leadless pacemaker implants, and lead-based device implants. That's the point when, as John was saying then, he'd look to bring on a colleague to train up and start implanting alongside him so they can start to share.
Once you get into that level, you've established those internal referral pathways, and that's the time at which you bring on additional one or two implanters.
Andrew, I think it's time to wrap it up. Thank you, everybody, for attending. We appreciate it, and looking forward to the next announcements. Thanks again for your support.
Thanks all.